RASAGILINE MYLAN Tablet Ref.[7501] Active ingredients: Rasagiline

Source: European Medicines Agency (EU)  Revision Year: 2021  Publisher: Mylan Pharmaceuticals Limited, Damastown Industrial Park, Mulhuddart, Dublin 15, DUBLIN Ireland

Product name and form

Rasagiline Mylan 1 mg tablets.

Pharmaceutical Form

Tablet.

White to off-white, oblong (approximately 11.5 mm x 6 mm) biconvex tablets, debossed with ‘R9SE’ on one side and ‘1’ on the other side.

Qualitative and quantitative composition

Each tablet contains rasagiline tartrate corresponding to 1 mg rasagiline.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Rasagiline

Rasagiline was shown to be a potent, irreversible MAO-B selective inhibitor, which may cause an increase in extracellular levels of dopamine in the striatum. The elevated dopamine level and subsequent increased dopaminergic activity are likely to mediate rasagiline’s beneficial effects seen in models of dopaminergic motor dysfunction.

List of Excipients

Cellulose, microcrystalline
Tartaric acid
Maize starch
Starch, pregelatinised maize
Talc
Stearic acid

Pack sizes and marketing

oPA/Al/PVC/Al. Blister packs of 7, 10, 28, 30, 100 or 112 tablets

PVC/PVDC/Al. Blister packs of 7, 10, 28, 30, 100 or 112 tablets

PVC/PVDC/Al. Perforated unit dose blister packs of 7 × 1, 10 × 1, 28 × 1, 30 × 1, 100 × 1 or 112 × 1.

Not all pack sizes may be marketed.

Marketing authorization holder

Mylan Pharmaceuticals Limited, Damastown Industrial Park, Mulhuddart, Dublin 15, DUBLIN Ireland

Marketing authorization dates and numbers

EU/1/16/1090/001 (7 tablets – oPA/alu/PVC/alu)
EU/1/16/1090/002 (10 tablets – oPA/alu/PVC/alu)
EU/1/16/1090/003 (28 tablets – oPA/alu/PVC/alu)
EU/1/16/1090/004 (30 tablets – oPA/alu/PVC/alu)
EU/1/16/1090/005 (100 tablets – oPA/alu/PVC/alu)
EU/1/16/1090/006 (112 tablets – oPA/alu/PVC/alu)
EU/1/16/1090/007 (7 tablets – PVC/PVDC/alu)
EU/1/16/1090/008 (10 tablets – PVC/PVDC/alu)
EU/1/16/1090/009 (28 tablets – PVC/PVDC/alu)
EU/1/16/1090/010 (30 tablets – PVC/PVDC/alu)
EU/1/16/1090/011 (100 tablets – PVC/PVDC/alu)
EU/1/16/1090/012 (112 tablets – PVC/PVDC/alu)
EU/1/16/1090/013 (7 tablets – PVC/PVDC/alu)
EU/1/16/1090/014 (10 tablets – PVC/PVDC/alu)
EU/1/16/1090/015 (28 tablets – PVC/PVDC/alu)
EU/1/16/1090/016 (30 tablets – PVC/PVDC/alu)
EU/1/16/1090/017 (100 tablets – PVC/PVDC/alu)
EU/1/16/1090/018 (112 tablets – PVC/PVDC/alu)

Date of first authorisation: 4 April 2016
Date of latest renewal: 20 November 2020

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.